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Background: The aim of this study was to investigate clinicopathologic features of type 3 gastric neuroendocrine neoplasm 
(NEN) by treatment modality. 
Methods: The Korean Society of Gastrointestinal Cancer conducted the Korean Gastroenteropancreatic Neuroendocrine 
Tumor Registry, a retrospective registry database of gastroenteropancreatic neuroendocrine tumors from 16 hospitals 
in Korea. The normal serum gastrin level range was defined as <100 pg/mL, and gastric NEN patients with normal gastrin
level were selected for analysis. 
Results: Among 358 patients with gastric NEN, 21 (5.9%) patients were classified with type 3 gastric NEN. The median 
age was 53 years (range 30-74). According to the WHO 2010 classification, 13 (61.9%) patients had grade 1, and 8
(38.1%) patients had grade 2 or 3. Endoscopic treatment was performed in 14 (66.7%) patients, and surgery was per-
formed in 7 (33.3%) patients. The tumor size was smaller in the endoscopic treatment group than in the surgery group 
(0.6 cm vs 1.3 cm, p=0.006). After treatment, there was one recurrence in the surgery group. 
Conclusion: In small size Type 3 gastric NEN, endoscopic treatment was associated with a good prognosis, compared 
to surgery. Thus, endoscopic treatment can be used an alternative modality in selected cases of type 3 gastric NEN.
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INTRODUCTION
Gastric neuroendocrine neoplasms (NENs) are a rare con-
dition, however, the incidence has increased, due to wide-
spread endoscopic surveillance.1,2 Gastric NENs account for 
6-8 percent of gastrointestinal NENs.1,2 Evidence for gastric 
NEN pathogenesis and advances in clinical treatment have 
evolved as diagnostic and treatment approaches have been 
investigated and developed.
In 1993, Rindi et al. first classified gastric NENs into three 
types: type 1, arising on chronic atrophic gastritis in the con- 
text of pernicious anemia; type 2, multiple endocrine neo-
plasms (MEN-I)/gastrin-producing neoplasm in Zollinger- 
Ellison syndrome; type 3, no specific background disease.3 
Type 1 and 2 gastric NENs are related to hypergastrinemia 
and type 3 gastric NENs occur sporadically, irrespective of 
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Table 1. Baseline characteristics
Parameter Values (median)
n 21
Age, years 53 (range 30-74)
Gender (male: female)  9:12
Gastrin (pg/mL) 45.1 (range 0.05-98.0)
Tumor location
 Antrum  1 (4.8%)
 Body 18 (85.7%)
 Fundus  3 (9.5%)
Tumor size 
 Endoscopy (cm)  0.95 (range 0.2-6.0)
 Pathology (cm)  0.8 (range 0.3-8.0)
WHO 2010
 G1 13 (61.9%)
 G2  7 (33.4%)
 G3  1 (4.7%)
Treatment
 Endoscopic resection 14 (66.7%)
  Surgery  7 (33.3%)
   Gastrectomy  4
   Wedge resection  3
Stage
 T1 11 (52.4%)
 T2 10 (47.6%)
Follow-up time (months) 27 (range 6-115)
WHO, World Health Organization; 
gastrin 3. Type 1 and 2 gastric NENs are considered to be 
benign and are associated with a good prognosis.4,5 However, 
type 3 gastric NEN is aggressive and is associated with lower 
overall survival.6,7 Endoscopic resection is an effective treat-
ment for type 1 and 2 gastric NENs. However type 3 gastric 
NEN requires gastrectomy and lymph node dissection for 
curative treatment and good outcomes.4,8
Some studies have recently shown the efficacy of endo-
scopic resection in type 3 gastric NENs. A recent study repor- 
ted that endoscopic resection could be considered for type 
3 gastric NEN that presented with a less than 2 cm-sized 
confined submucosal layer.9 However, there are only a limited 
number of studies that have compared endoscopic resection 
and surgery treatment results for type 3 gastric NEN. The 
aim of this study was to investigate the clinicopathologic fea- 
tures of type 3 gastric NEN according to treatment modality.
MATERIALS AND METHODS
The Korean Gastroenteropanreatic Neuroendocrine Tumor 
Registry was conducted by The Korean Society of Gastroin- 
testinal Cancer from 2012. This registry was a retrospective 
database of gastroenteropancreatic neuroendocrine neoplasm 
collected from 16 tertiary hospitals in Korea. The registry 
database and standard analyzing protocols were approved 
by each institutional review board of all participating hos- 
pitals. Between January 2002 and December 2012, a total 
of 358 patients with gastric NENs were registered. Type 3 
gastric NEN was defined as NEN with serum gastrin level less 
than 100 pg/mL and not associated with MEN-1 or Zollinger- 
Ellison syndrome. 
Gastric NEN treatment was determined by the gastroen- 
terologists in each hospital, considering tumor size, number 
of tumors, depth of tumor and lymph node involvement 
by computed tomography and endoscopic ultrasonography, 
with endoscopic resection or surgery. Endoscopic mucosal 
resection or endoscopic submucosal resection was performed 
in the endoscopic treatment group. Wedge resection, subtotal 
gastrectomy or total gastrectomy was performed in the sur-
gery group.
Continuous variable data were presented as the median 
with ranges. To compare the two surgery and endoscopic 
treatment approaches, the Mann-Whitney U-test was used 
for continuous variables, and Fisher’s exact test was used for 
categorical variables. A p-value of 0.05 was considered statisti-
cally significant. All statistical analyses were performed using 
SPSS version 18.0 for Windows (SPSS Inc. Chicago, IL, USA).
RESULTS
From the total of 358 patients with gastric NEN, 21 patients 
had type 3 NEN (Table 1). The median age was 53 years 
(range 30-74). Nine patients (43%) were male and twelve 
patients (57%) were female. Eight patients (38%) had abdo- 
minal pain or discomfort and thirteen patients (62%) were 
asymptomatic. The median gastrin level was 45.1 pg/mL 
(range 0.05-98). The tumor was mostly located within the 
organ body (85.7%). The median tumor size was 0.95 cm, 
based on endoscopy results (range 0.2-6.0).
Fourteen patients received endoscopic treatment including 
endoscopic mucosal resection (n=4) and endoscopic submu- 
cosal resection (n=10). Seven patients underwent surgery 
(Fig. 1). The age, gender, serum gastrin level and tumor loca- 
tion were not different between the two groups (Table 2). 
Tumor size was smaller in the endoscopic treatment group
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Fig. 1. Flow chart.
Table 2. Clinicopathologic findings based on treatment modality
Parameter (median)
Treatment
p
Endoscopy Surgery
n 14  7
Age (yrs) 53 (range 30-69) 54 (range 35-74) 0.390
Gender (male: female)  4:10  5:2 0.687
Gastrin (pg/mL) 49.8 (range 0.05-98.0) 40.8 (range 4.5-77.7) 0.941
Tumor location 0.407
  Antrum  0  1 (14.3%)
Body 12 (85.7%)  6 (85.7%)
Fundus  2 (14.3%)  0
Tumor size (Before resection)  0.8 (range 0.2-1.5)  1.75 (range 1.5-6.0) 0.001
Tumor size (After resection)  0.6 (range 0.3-1.6)  1.3 (range 0.8-8.0) 0.006
WHO 2010 0.333
  G1 & G2 14 (100%)  6 (85.7%)
  G3  0  1 (14.3%
T Stage 0.001
T1 11 (78.6%)  0
T2  3 (21.4%)  7 (100%)
N stage -
N0 -  4 (57.1%)
N1 -  3 (42.9%)
*Mann-Whitney U-test was used for continuous variables, Fisher’s exact test was used for categorical variables.
WHO, World Health Organization;
Table 3. Treatment outcomes
Parameter 
Treatment
p
Endoscopy (n=14) Surgery (n=7)
Complete remission 14 (100%) 6 (85.7%) 0.333
Recurrence  0 1 (14.3%)
Mortality  0 1 (14.3%)
*Fisher’s exact test was used
than in the surgery group (0.6cm vs. 1.3 cm, p=0.006). WHO 
2010 grade was not significantly different between the groups. 
However, there were more T2 disease diagnoses in the surgery 
group compared to the endoscopic treatment group (p= 
0.001). During follow-up, there was no recurrence in the 
endoscopic treatment group but there was one recurrence 
in the surgery group (p=0.333). The patient with recurrence 
was initially diagnosed as G3 disease stage, according to WHO 
2010 guidelines and experienced recurrence 7 months after 
subtotal gastrectomy (Table 3). 
DISCUSSION
The incidence of gastric NENs is increasing due to the ad- 
vent of screening endoscopy. Gastric NENs are usually diag-
nosed at an early stage and incidentally.10 Surgery is an accep- 
table treatment in patients with gastric NENs.11,12 However, 
the treatment paradigm has changed as tumor behavior and 
treatment modalities are being investigated since gastric NENs 
were classified into 3 types. 
The three types of gastric NEN have distinct endoscopic 
and histologic findings. Type 1 gastric NENs are often found 
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in the fundus and are mostly polypoid (78%), small (5-8 mm) 
and multicentric.13,14 Histologically, most type 1 gastric NENs 
are G1 tumors with low Ki67 that are limited to the mucosa 
or submucosa.13,15 Type 2 gastric NENs are usually less than 
1 cm and multicentric.16 Histologically, type 2 NENs are 
usually well-differentiated (G1 or G2). However, type 2 
NENs are more frequently identified in metastases to abdomi-
nal lymph nodes and liver, compared with type 1 NENs 3. 
In comparison with type 1 and 2 gastric NENs, type 3 gastric 
NENs present as large (>2 cm) solitary lesions that grow 
from the normal gastric mucosa.9 G3 (neuroendocrine carci-
noma) is more common in type 3 gastric NENs. In addition, 
deep wall invasion is common and 60-75% of cases present 
with metastases.3,17 Therefore, type 3 gastric NENs have an 
aggressive behavior and are associated with the poorest pro- 
gnoses. 
Type 1 and 2 gastric NENs that are within the submucosal 
layer are commonly treated by endoscopy.18 In contrast, the 
standard treatment for type 3 gastric NENs is partial gastre- 
ctomy or total gastrectomy with local lymph node dissection. 
19,20 Additional systemic chemotherapy is needed if the surgi-
cal result is not satisfactory or if surgery is not feasible.21 
Because partial gastrectomy and total gastrectomy are relati- 
vely invasive procedures, the risk of postoperative adverse 
events and the quality of life are a serious concern.22,23 A 
recent study reported that gastric neuroendocrine tumor G1 
types that have not yet advanced can be treated with endo-
scopic or laparoscopic surgery.24 Another study reported that 
endoscopic treatment could be considered in cases where the 
tumor was less than 2 cm and confined to the submucosal 
layer and type 3 gastric NEN could be treated when there was 
no evidence of lymphovascular invasion.9 Fifty patients with 
type 3 gastric NEN were treated with endoscopic mucosal 
resection (n=41) or endoscopic submucosal dissection (n=9) 
and during the follow-up period, there was no evidence of 
recurrence.9
In this study, we compared the treatment results in type 
3 gastric NEN, based on treatment modality. To our knowledge, 
this is the first investigation to compare the treatment modal-
ity for type 3 gastric NENs. We used the Korean Gastroentero- 
pancreatic Neuroendocrine Tumor Study in the Korean So- 
ciety of Gastrointestinal Cancer and identified 21 patients 
with type 3 gastric NENs that were retrospectively enrolled 
from 16 tertiary hospitals. Fourteen patients received endo-
scopic treatment and seven patients underwent surgery. The 
treatment modality was decided after estimating the tumor 
size by endoscopy. If the tumor size was small and confined 
to the submucosal layer, endoscopic treatment was initially 
applied. The surgery group had larger tumor sizes and more 
lymph node metastases. There was one case with recurrence 
in the surgery group, in which the patient was diagnosed 
with stage G3 and lymph node metastasis. A recent study 
reported that there were no cases of lymphovascular, perineu- 
ral invasion or lymph node metastasis among G1 or 2 patients 
with less than 1 cm-sized lesions.25 Our study found similar 
results. Therefore, careful selection of patients is very impor- 
tant for accurately assigning treatment modality.
There were some limitations to this study. First, the study 
was retrospective and the number of enrolled patients were 
small, even though 16 tertiary hospitals participated. Many 
patients with gastric NEN did not evaluate the level of gastrin. 
Therefore, the number of type 3 gastric NEN might have 
been underestimated. Second, although G3 are known to be 
common in type 3 gastric NENs, there was only one case 
with G3 in this study. This might have introduced a selection 
bias. Third, the progression free survival and overall survival 
were not evaluated. Because there was only on incidence 
of recurrence in the surgery group, the survival could not 
be analyzed. However, this study assessed a relatively large 
numbers of type 3 gastric NENs and compared the treatment 
results. Therefore, the results of this study can provide guid-
ance for assessment and treatment modality in type 3 gastric 
NENs. 
In conclusion, endoscopic treatment showed similar treat-
ment results when compared to surgery on small size (less than 
1 cm) tumors that were confined to the submucosal layer in 
patients with type 3 gastric NENs. Additional research is 
needed and large and randomized controlled studies are needed 
to further assess the applications of the results of this study.
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